Our western blot results showed that Spautin-1 notably decreased the levels of Tyr1068-phosphorylated EGFR and Tyr1173-phosphorylated EGFR but did not decrease total EGFR protein levels in 22Rv1 and PC3 cells (Fig. 5a), and these effects induced by Spautin-1 were paralleled with the effects of gefitinib, a classic EGFR-TKI (Fig. 5b), indicating that Spuatin-1 suppresses EGFR activation in prostate cancers. The gene discussed is EGFR; the disease is prostate cancer.